Cervical Cancer - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 472
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CE54C688042EN
Leaflet:

Download PDF Leaflet

Cervical Cancer - Pipeline Review, H2 2016
Cervical Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer – Pipeline Review, H2 2016, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 20, 29, 1, 39, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 5 molecules, respectively.Cervical Cancer.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cervical Cancer Overview
Therapeutics Development
Pipeline Products for Cervical Cancer - Overview
Pipeline Products for Cervical Cancer - Comparative Analysis
Cervical Cancer - Therapeutics under Development by Companies
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes
Cervical Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cervical Cancer - Products under Development by Companies
Cervical Cancer - Products under Investigation by Universities/Institutes
Cervical Cancer - Companies Involved in Therapeutics Development
Abion Inc
Admedus Ltd
Advaxis Inc
Advenchen Laboratories LLC
Antigen Express Inc
Arbor Vita Corp
ArQule Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Azaya Therapeutics Inc
Bioleaders Corporation
Biomics Biotechnologies Co Ltd
Blirt SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cancer Research Technology Ltd
Cell Medica Ltd
Cellceutix Corp
Coherus BioSciences Inc
Critical Outcome Technologies Inc
CZ BioMed Corp
DelMar Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Ltd
EirGenix Inc.
Eisai Co Ltd
Etubics Corp
Eureka Therapeutics Inc
EyeGene Inc
F. Hoffmann-La Roche Ltd
Formune SL
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genexine Inc
Genmab A/S
Genor BioPharma Co Ltd
Genticel S.A.
GlaxoSmithKline Plc
Immune Therapeutics, Inc.
Immunovaccine Inc
INSYS Therapeutics Inc
ISA Pharmaceuticals BV
Johnson & Johnson
Karyopharm Therapeutics Inc
Kite Pharma Inc
LondonPharma Ltd
Mabion SA
Merck & Co Inc
Mycenax Biotech Inc
Nanotherapeutics Inc
Nektar Therapeutics
Oncobiologics Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
PDS Biotechnology Corp
Pfizer Inc
Psicofarma SA de CV
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Savoy Pharmaceuticals, Inc.
Seattle Genetics Inc
Selecta Biosciences Inc
Shantha Biotechnics Ltd
Sirnaomics Inc
Sun Pharma Advanced Research Company Ltd
Taiho Pharmaceutical Co Ltd
Tessa Therapeutics Pte Ltd
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Tomegavax Inc
UbiVac LLC
VLPbio
Zeria Pharmaceutical Co Ltd
Zydus Cadila Healthcare Ltd
Cervical Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(hydralazine + valproate magnesium) - Drug Profile
ABN-301 - Drug Profile
AEH-10p - Drug Profile
AL-3818 - Drug Profile
Ancer - Drug Profile
Antisense RNAi Oligonucleotide for Cervical Cancer - Drug Profile
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
ARQ-092 - Drug Profile
artemether - Drug Profile
atezolizumab - Drug Profile
AV-203 - Drug Profile
AVC-7 - Drug Profile
axalimogene filolisbac - Drug Profile
AZD-5363 - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
BLR-111 - Drug Profile
BLSILSB-710c - Drug Profile
BMS-986016 - Drug Profile
BVAC-C - Drug Profile
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile
CerviVax - Drug Profile
Cervlysis - Drug Profile
CIGB-300 - Drug Profile
CMD-004 - Drug Profile
COTI-2 - Drug Profile
crocetin - Drug Profile
dianhydrogalactitol - Drug Profile
docetaxel - Drug Profile
DPXE-7 - Drug Profile
E-7046 - Drug Profile
EDA-HPVE7 - Drug Profile
EDOB-278 - Drug Profile
EF-022 - Drug Profile
EG-HPV - Drug Profile
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
ET-1502 - Drug Profile
ETBX-041 - Drug Profile
etirinotecan pegol - Drug Profile
GM-102 - Drug Profile
GSK-2256098 - Drug Profile
GSK-2849330 - Drug Profile
GTL-001 - Drug Profile
GTL-002 - Drug Profile
GX-I7 - Drug Profile
HPViNT - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile
ISA-101 - Drug Profile
JNJ-61610588 - Drug Profile
Kevetrin - Drug Profile
KITE-439 - Drug Profile
LN-145 - Drug Profile
Lovaxin S - Drug Profile
Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer - Drug Profile
naltrexone hydrochloride - Drug Profile
nimotuzumab - Drug Profile
nintedanib - Drug Profile
NIT-02 - Drug Profile
nivolumab - Drug Profile
NP-001 - Drug Profile
NTO-1151 - Drug Profile
Oncoprev - Drug Profile
OTAC-DCtag - Drug Profile
paclitaxel - Drug Profile
paclitaxel - Drug Profile
paclitaxel albumin free - Drug Profile
PDS-0101 - Drug Profile
pembrolizumab - Drug Profile
PF-04518600 - Drug Profile
phosphoethanolamine - Drug Profile
RA-190 - Drug Profile
Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer - Drug Profile
RG-7876 - Drug Profile
RX-3117 - Drug Profile
S-009131 - Drug Profile
SAR-408701 - Drug Profile
SEL-701 - Drug Profile
selinexor - Drug Profile
SGN-LIV1A - Drug Profile
sirolimus albumin-bound - Drug Profile
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile
STP-900 - Drug Profile
Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile
Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile
TA-CIN - Drug Profile
TAS-114 - Drug Profile
Tenacinol - Drug Profile
tisotumab vedotin - Drug Profile
TT-12 - Drug Profile
TVGV-1 - Drug Profile
utomilumab - Drug Profile
Vaccine for HPV Associated Cancers - Drug Profile
Vaccine for HPV Associated Cervical Cancer - Drug Profile
Vaccine for HPV Associated Cervical Cancer - Drug Profile
Vaccine for HPV Associated Cervical Cancer - Drug Profile
Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile
Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer - Drug Profile
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
Vicoryx - Drug Profile
Vvax-001 - Drug Profile
Cervical Cancer - Dormant Projects
Cervical Cancer - Discontinued Products
Cervical Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 46

LIST OF TABLES

Number of Products under Development for Cervical Cancer, H2 2016
Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2016
Cervical Cancer - Pipeline by Abion Inc, H2 2016
Cervical Cancer - Pipeline by Admedus Ltd, H2 2016
Cervical Cancer - Pipeline by Advaxis Inc, H2 2016
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
Cervical Cancer - Pipeline by Antigen Express Inc, H2 2016
Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2016
Cervical Cancer - Pipeline by ArQule Inc, H2 2016
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2016
Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Cervical Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
Cervical Cancer - Pipeline by Bioleaders Corporation, H2 2016
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016
Cervical Cancer - Pipeline by Blirt SA, H2 2016
Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2016
Cervical Cancer - Pipeline by Cell Medica Ltd, H2 2016
Cervical Cancer - Pipeline by Cellceutix Corp, H2 2016
Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2016
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2016
Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H2 2016
Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
Cervical Cancer - Pipeline by EirGenix Inc., H2 2016
Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2016
Cervical Cancer - Pipeline by Etubics Corp, H2 2016
Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016
Cervical Cancer - Pipeline by EyeGene Inc, H2 2016
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Cervical Cancer - Pipeline by Formune SL, H2 2016
Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2016
Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
Cervical Cancer - Pipeline by Genexine Inc, H2 2016
Cervical Cancer - Pipeline by Genmab A/S, H2 2016
Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
Cervical Cancer - Pipeline by Genticel S.A., H2 2016
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Cervical Cancer - Pipeline by Immune Therapeutics, Inc., H2 2016
Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2016
Cervical Cancer - Pipeline by INSYS Therapeutics Inc, H2 2016
Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016
Cervical Cancer - Pipeline by Johnson & Johnson, H2 2016
Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2016
Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2016
Cervical Cancer - Pipeline by Mabion SA, H2 2016
Cervical Cancer - Pipeline by Merck & Co Inc, H2 2016
Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2016
Cervical Cancer - Pipeline by Nanotherapeutics Inc, H2 2016
Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2016
Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2016
Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016
Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2016
Cervical Cancer - Pipeline by Pfizer Inc, H2 2016
Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2016
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016
Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2016
Cervical Cancer - Pipeline by Sanofi, H2 2016
Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2016
Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2016
Cervical Cancer - Pipeline by Shantha Biotechnics Ltd, H2 2016
Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2016
Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
Cervical Cancer - Pipeline by Theravectys SA, H2 2016
Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016
Cervical Cancer - Pipeline by Tomegavax Inc, H2 2016
Cervical Cancer - Pipeline by UbiVac LLC, H2 2016
Cervical Cancer - Pipeline by VLPbio, H2 2016
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2016
Cervical Cancer - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cervical Cancer - Dormant Projects, H2 2016
Cervical Cancer - Dormant Projects (Contd..1), H2 2016
Cervical Cancer - Dormant Projects (Contd..2), H2 2016
Cervical Cancer - Dormant Projects (Contd..3), H2 2016
Cervical Cancer - Dormant Projects (Contd..4), H2 2016
Cervical Cancer - Dormant Projects (Contd..5), H2 2016
Cervical Cancer - Dormant Projects (Contd..6), H2 2016
Cervical Cancer - Discontinued Products, H2 2016 45

LIST OF FIGURES

Number of Products under Development for Cervical Cancer, H2 2016
Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Cervical Dysplasia - Pipeline Review, H2 2014 US$ 1,600.00 Dec, 2014 · 66 pages

Ask Your Question

Cervical Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: